[go: up one dir, main page]

NO980335D0 - Stabilt isotont lyofilisert proteinpreparat - Google Patents

Stabilt isotont lyofilisert proteinpreparat

Info

Publication number
NO980335D0
NO980335D0 NO980335A NO980335A NO980335D0 NO 980335 D0 NO980335 D0 NO 980335D0 NO 980335 A NO980335 A NO 980335A NO 980335 A NO980335 A NO 980335A NO 980335 D0 NO980335 D0 NO 980335D0
Authority
NO
Norway
Prior art keywords
protein preparation
lyophilized protein
reconstituted
stable isotonic
stable
Prior art date
Application number
NO980335A
Other languages
English (en)
Other versions
NO323557B1 (no
NO323557B3 (no
NO980335L (no
Inventor
James Andya
Jeffrey L Cleland
Chung C Hsu
Xanthe M Lam
David E Overcashier
Steven J Shire
Janet Yu-Feng Yang
Sylvia Sau-Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27056058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO980335(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/615,369 external-priority patent/US6267958B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO980335D0 publication Critical patent/NO980335D0/no
Publication of NO980335L publication Critical patent/NO980335L/no
Publication of NO323557B1 publication Critical patent/NO323557B1/no
Publication of NO323557B3 publication Critical patent/NO323557B3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO19980335A 1995-07-27 1998-01-26 Stabil, rekonstituert formulering og lyofilisert formulering, fremgangsmåte for fremstilling av disse, fremstilt artikkel og anvendelse av formuleringene. NO323557B3 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US08/615,369 US6267958B1 (en) 1995-07-27 1996-03-14 Protein formulation
PCT/US1996/012251 WO1997004801A1 (en) 1995-07-27 1996-07-23 Stabile isotonic lyophilized protein formulation

Publications (4)

Publication Number Publication Date
NO980335D0 true NO980335D0 (no) 1998-01-26
NO980335L NO980335L (no) 1998-03-26
NO323557B1 NO323557B1 (no) 2007-06-11
NO323557B3 NO323557B3 (no) 2007-06-11

Family

ID=27056058

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19980335A NO323557B3 (no) 1995-07-27 1998-01-26 Stabil, rekonstituert formulering og lyofilisert formulering, fremgangsmåte for fremstilling av disse, fremstilt artikkel og anvendelse av formuleringene.
NO2007012C NO2007012I1 (no) 1995-07-27 2007-11-05 Trastuzumab eller farmasoytisk akseptable salter derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2007012C NO2007012I1 (no) 1995-07-27 2007-11-05 Trastuzumab eller farmasoytisk akseptable salter derav

Country Status (17)

Country Link
EP (3) EP2275119B1 (no)
JP (7) JPH11510170A (no)
CN (3) CN102416176A (no)
AR (2) AR003969A1 (no)
AU (1) AU716785B2 (no)
BR (1) BR9609743A (no)
CA (2) CA2226575C (no)
DK (2) DK2275119T3 (no)
ES (2) ES2435462T3 (no)
IL (1) IL122910A (no)
MX (1) MX9800684A (no)
NO (2) NO323557B3 (no)
NZ (2) NZ500539A (no)
PT (2) PT1516628E (no)
RU (2) RU2497500C2 (no)
SI (2) SI2275119T1 (no)
WO (1) WO1997004801A1 (no)

Families Citing this family (370)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1998056418A1 (en) * 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
CZ302005B6 (cs) * 1998-03-26 2010-09-01 Schering Corporation Vodný prostredek PEG-interferon alfa konjugátu, jeho lyofilizát a výrobek jej obsahující
ES2292682T3 (es) * 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
WO2000052054A2 (en) 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP4557098B2 (ja) * 1999-03-31 2010-10-06 味の素株式会社 安定な６−アミジノ−２−ナフチル４−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法
CN100448482C (zh) * 1999-05-31 2009-01-07 三菱化学株式会社 Hgf冻干制剂
CA2376894C (en) 1999-06-12 2009-10-20 Bitop Gmbh Pharmaceutical composition comprising a protein and an ectoine
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
PT2283866E (pt) 1999-06-25 2015-07-20 Genentech Inc Métodos de tratamento utilizando conjugados de anticorpo anti-erbb-maitansinóide
PL204629B1 (pl) 1999-06-25 2010-01-29 Genentech Inc Zastosowanie przeciwciała do wytwarzania leku do leczenia raka sutka, zastosowanie przeciwciała do leczenia raka jajnika, zastosowanie przeciwciała do wytwarzania leku do leczenia raka płuc i zastosowanie przeciwciała do leczenia raka okrężnicy, raka odbytnicy i raka jelita grubego i odbytu
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
EP1064934A1 (en) 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
SI1210115T1 (sl) 1999-08-27 2009-12-31 Genentech Inc Doziranja za zdravljenje s protitelesi proti ErbB2
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CN100389821C (zh) * 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
CA2393298C (en) * 1999-12-02 2011-02-01 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
KR100771294B1 (ko) 1999-12-14 2007-10-29 써모 바이오스타, 인크. 폴리펩티드 및 항원 안정화 희석제
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
KR100850727B1 (ko) 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2444661A1 (en) 2001-01-31 2002-08-08 Idec Pharmaceutical Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
EP1404871A4 (en) 2001-05-23 2006-10-04 Sloan Kettering Inst Cancer METHOD OF TREATING CANCERS ASSOCIATED WITH LEVELS OF HER-2 STUDENTS
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
NZ532896A (en) 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
CN100415769C (zh) * 2002-02-07 2008-09-03 中国科学院过程工程研究所 寡聚或多聚亚基蛋白质分离纯化的方法
PL213311B1 (pl) 2002-02-14 2013-02-28 Chugai Pharmaceutical Co Ltd Preparat roztworu zawierajacego przeciwcialo
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
SI2289942T1 (sl) 2002-04-10 2013-11-29 Genentech, Inc. Variante protitelesa proti HER2
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
NZ537610A (en) * 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004071439A2 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
CA2518903C (en) 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
AU2012200957B2 (en) * 2003-04-04 2014-10-23 Genentech, Inc. High concentration antibody and protein formulations
RU2358762C9 (ru) 2003-04-09 2016-10-10 Джинентех, Инк. Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2281577B1 (en) 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
EP2272868B1 (en) 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
PT1638595E (pt) 2003-06-20 2013-04-26 Ares Trading Sa Fsh liofilizada / formulações de hl
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
EP1664398A4 (en) 2003-09-03 2009-08-26 Shmuel Bukshpan METHODS AND DEVICES FOR REALIZING RAPID CRYSTALLIZATION OF BIOLOGICAL MOLECULES
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
WO2005089503A2 (en) * 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
US7319032B2 (en) 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
DE102004022927A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
CA2589889C (en) * 2004-12-15 2013-07-30 Amgen Inc. Therapeutic formulations of keratinocyte growth factor
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
CN1313161C (zh) * 2005-01-27 2007-05-02 北京大学临床肿瘤学院 结直肠癌放射免疫导向手术药物及其制备方法
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
RU2488597C2 (ru) 2005-02-07 2013-07-27 Гликарт Биотехнологи Аг Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
HUE027096T2 (en) * 2005-03-25 2016-08-29 Regeneron Pharma VEGF antagonist formulations
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
AR055137A1 (es) 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
US20070237758A1 (en) * 2005-11-22 2007-10-11 Anthony Barry Immunoglobulin fusion protein formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
ES2391657T3 (es) * 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
AU2007227224A1 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CN101199483B (zh) * 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
CN101199845B (zh) * 2006-12-14 2012-05-23 上海国健生物技术研究院 一种稳定的抗IgE人源化单抗制剂
AR064826A1 (es) * 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
JP2010519220A (ja) * 2007-02-16 2010-06-03 ワイス エルエルシー マンニトール誘導性のタンパク質凝集を抑制するためのスクロースの使用
EP2132573B1 (en) 2007-03-02 2014-04-23 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
EP2198021A4 (en) 2007-08-24 2011-01-19 Oncotherapy Science Inc EBI3, DLX5, NPTX1, and CDKN3 for target genes of lung cancer therapy and diagnosis
JP2010536844A (ja) 2007-08-24 2010-12-02 オンコセラピー・サイエンス株式会社 癌の治療標的及び診断マーカーとしてのｄｋｋ１癌遺伝子
KR20090056543A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858B (zh) 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
AU2008346734A1 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
EP2085095B1 (en) 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CA2716919C (en) 2008-03-14 2015-01-20 Biocon Limited An anti-cd6 monoclonal antibody and use thereof
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
ES2532635T3 (es) 2008-07-15 2015-03-30 Genentech, Inc. Conjugados de antraciclina, proceso para su preparación y su uso como compuestos antitumorales
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
SI2349314T1 (sl) 2008-10-21 2013-05-31 Baxter International Inc. Liofilizirane rekombinantne VWF formulacije
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
US9393304B2 (en) * 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
EP2752189B1 (en) 2008-11-22 2016-10-26 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
CN102365297B (zh) 2009-03-25 2014-10-29 霍夫曼-拉罗奇有限公司 新型抗-α5β1抗体及其应用
SG174963A1 (en) 2009-03-31 2011-11-28 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
UA105384C2 (ru) 2009-04-01 2014-05-12 Дженентек, Инк. Лечение нарушений, связанных с инсулинорезистентностью
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
MX379016B (es) 2009-07-28 2025-03-10 Takeda Pharmaceuticals Co Composiciones y metodos para tratar enfermedad de gaucher.
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010284446A1 (en) 2009-08-15 2012-03-08 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
SI3133083T1 (sl) 2009-10-01 2020-07-31 F. Hoffmann-La Roche Ag Končna filtracija v več korakih
EP3721904B1 (en) * 2009-11-20 2021-10-13 Biocon Limited Formulations of t1h antibody
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
BR112012014721B1 (pt) 2009-12-15 2022-06-28 Ascendis Pharma Endocrinology Division A/S Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit
MX2012007676A (es) * 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
ES2648139T3 (es) 2010-02-19 2017-12-28 Cadila Pharmaceuticals Ltd. Una composición farmacéutica de células muertas con inmunogenicidad sustancialmente retenida
RU2012140447A (ru) 2010-02-23 2014-03-27 Дженентек, Инк. Антиангиогенная терапия для лечения рака яичника
PL2542257T3 (pl) 2010-03-01 2018-01-31 Bayer Healthcare Llc Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
CN105521491B (zh) 2010-03-01 2020-03-24 西托戴恩有限公司 浓缩蛋白制剂及其用途
JP6023696B2 (ja) 2010-03-31 2016-11-09 スタビリテック リミテッド ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化
EP2552478B1 (en) 2010-03-31 2016-12-21 Stabilitech Ltd. Excipients for stabilising viral particles
AU2011247659B2 (en) * 2010-04-27 2014-07-24 Scil Technology Gmbh Stable aqueous MIA/CD-RAP formulations
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
MX339666B (es) 2010-06-24 2016-06-03 Genentech Inc * Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
SG186421A1 (en) * 2010-07-02 2013-01-30 Medimmune Llc Antibody formulations
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
EP2596128B1 (en) 2010-07-22 2015-04-22 President and Fellows of Harvard College Multiple input biologic classifier circuits for cells
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
PT2624865T (pt) * 2010-10-06 2018-11-05 Regeneron Pharma Formulações estabilizadas que contêm anticorpos anti-recetor de interleucina-4 (il-4r)
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
MX350932B (es) 2010-12-02 2017-09-26 Oncolytics Biotech Inc Formulaciones virales liquidas.
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
CN102028661B (zh) * 2010-12-31 2012-05-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
PL2668212T3 (pl) 2011-01-28 2018-08-31 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
MX341076B (es) 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
ES3023516T3 (en) 2011-10-14 2025-06-02 Hoffmann La Roche Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
MX391043B (es) * 2011-10-25 2025-03-21 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos.
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
EP2793941A1 (en) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies
CN102512384B (zh) * 2011-12-29 2014-11-26 嘉和生物药业有限公司 一种冻干剂型蛋白组合物及其制备方法
SI2825558T1 (sl) 2012-03-13 2019-08-30 F. Hoffmann-La Roche Ag Kombinirana terapija za zdravljenje raka jajčnikov
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
MX389346B (es) * 2012-05-18 2025-03-20 Genentech Inc Formulaciones de anticuerpos monoclonales de alta concentración.
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
KR20190088571A (ko) 2012-08-07 2019-07-26 제넨테크, 인크. 교모세포종의 치료를 위한 조합 요법
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014045213A1 (en) 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
WO2014045081A1 (en) 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
EP2911692B1 (en) 2012-10-26 2019-08-21 The University of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
EP2914289B1 (en) * 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MX367748B (es) * 2012-12-21 2019-09-04 Glenmark Pharmaceuticals Sa Formulación de anticuerpo anti her2.
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US11433029B2 (en) 2013-03-15 2022-09-06 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
PL3024485T3 (pl) 2013-07-23 2021-06-14 Biocon Limited Zastosowanie partnera wiążącego cd6 i oparty na tym sposób
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP4420729A3 (en) 2013-11-21 2024-10-30 Genmab A/S Antibody-drug conjugate formulation
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
CN103893135B (zh) * 2014-03-28 2017-01-11 中国医学科学院输血研究所 一种人血浆蛋白c的冻干稳定剂组合物及其用途
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
ES2910443T3 (es) * 2014-04-16 2022-05-12 Biocon Ltd Formulaciones de proteínas estables que comprenden un exceso molar de sorbitol
ES2974895T3 (es) 2014-05-07 2024-07-02 Takeda Pharmaceuticals Co Formulación líquida que comprende un compuesto neutralizante de GM-CSF
RU2019138024A (ru) * 2014-05-28 2019-12-05 Ноно Инк. ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9c, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
ES2761675T3 (es) 2014-05-30 2020-05-20 Henlix Biotech Co Ltd Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
CN106573961B (zh) 2014-06-20 2022-01-04 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
JP6634394B2 (ja) * 2014-06-26 2020-01-22 アムジェン インコーポレイテッド タンパク質製剤
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
EP3567056A1 (en) 2014-09-10 2019-11-13 F. Hoffmann-La Roche AG Galactoengineered immunoglobulin 1 antibodies
SG11201703237VA (en) 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
WO2016161390A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
WO2016169453A1 (zh) 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物及注射粉剂
EP3287140B1 (en) 2015-04-21 2021-06-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
JP6952605B2 (ja) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド 多特異性抗原結合タンパク質
DK3313879T3 (da) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
AU2016308111A1 (en) 2015-08-18 2018-03-01 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
LT3359572T (lt) 2015-10-06 2025-02-10 F. Hoffmann-La Roche Ag Išsėtinės sklerozės gydymo būdas
IL295808B2 (en) 2015-12-03 2023-10-01 Regeneron Pharma Methods for associating genetic variants with clinical outcome in patients suffering from age-related macular degeneration and receiving treatment against tubular endothelial growth factor
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US11389510B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
MX2018008544A (es) * 2016-01-12 2019-05-15 Intron Biotechnology Inc Formulaciones de proteina antibacteriana secadas por congelacion.
KR102669340B1 (ko) 2016-01-12 2024-05-28 주식회사 인트론바이오테크놀로지 항균 조성물 및 항균 조성물로 스태필로코커스 감염들을 치료하는 방법
JP2019505520A (ja) 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
JP2019515874A (ja) 2016-03-01 2019-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改変された細胞死誘導を有するオビヌツズマブ変異体
US11297828B2 (en) 2016-03-14 2022-04-12 The Regents Of The University Of Michigan Surface tension mediated lyo-processing technique for preservation of biologics
CN109154014A (zh) 2016-05-10 2019-01-04 豪夫迈·罗氏有限公司 重组产生多肽期间减少三硫键的方法
KR102783452B1 (ko) 2016-06-01 2025-03-19 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2018049275A1 (en) 2016-09-09 2018-03-15 Genentech, Inc. Selective peptide inhibitors of frizzled
RS67443B1 (sr) 2016-09-16 2025-12-31 Shanghai Henlius Biotech Inc Anti-pd-1 antitela za upotrebu u lečenju kancera
WO2018068012A1 (en) * 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
AU2017344462B2 (en) 2016-10-21 2024-07-25 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
CN110290800A (zh) 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
CA3047168A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof
CA3047174A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating liver fibrosis
US20190328848A1 (en) 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating drug-induced renal injury
CN110114079A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
JP7531080B2 (ja) 2016-12-15 2024-08-09 タレンゲン インターナショナル リミテッド 骨粗鬆症を予防及び治療するための薬物およびその用途
JP7171572B2 (ja) 2016-12-15 2022-11-15 タレンゲン インターナショナル リミテッド 糖尿病を治療するための新しい方法
CN110114081A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种改善心脏病变的方法
MX2019007801A (es) 2016-12-28 2019-10-30 Genentech Inc Tratamiento de cáncer avanzado con expresión de her2.
US11274157B2 (en) 2017-01-12 2022-03-15 Eureka Therapeutics, Inc. Constructs targeting histone H3 peptide/MHC complexes and uses thereof
ES2835376T3 (es) 2017-01-17 2021-06-22 Genentech Inc Formulaciones de anticuerpos frente a HER2 subcutáneas
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
SG10201913582XA (en) 2017-04-26 2020-02-27 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CN110198739B (zh) * 2017-05-16 2023-04-04 江苏恒瑞医药股份有限公司 一种pd-l1抗体药物组合物及其用途
EP3672982A4 (en) 2017-08-22 2021-06-09 Monash University SCREENING ASSAYS, MODULATORS AND MODULATION OF ACTIVATION OF THE RECEPTOR FOR ADVANCED GLYCING END PRODUCTS (RAGE)
KR102831164B1 (ko) 2017-10-30 2025-07-07 에프. 호프만-라 로슈 아게 단일특이적 항체로부터 다중특이적 항체의 생체내 생성 방법
SG11202004268PA (en) 2017-11-30 2020-06-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
CN111465408B (zh) 2017-12-15 2023-07-04 泰伦基国际有限公司 一种预防或治疗骨关节炎的方法和药物
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
RU2020135052A (ru) 2018-03-28 2022-04-29 Аксон Ньюросайенс Се Способы выявления и лечения болезни альцгеймера на основе антител
CR20250325A (es) 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
SG11202010993VA (en) 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
MX421310B (es) 2018-05-10 2025-03-14 Regeneron Pharma Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN117442717A (zh) 2018-06-01 2024-01-26 大有华夏生物医药集团有限公司 治疗疾病或病况的组合物及其用途
CN112469440B (zh) 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN112584863B (zh) 2018-08-17 2025-10-28 Ab工作室有限公司 催化抗体和其使用方法
US20210353715A1 (en) 2018-09-20 2021-11-18 Mandalmed, Inc. Methods and compositions for preventing, treating, and reversing liver fibrosis
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2020089743A1 (en) * 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
BR112021008873A8 (pt) 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
KR20210101235A (ko) 2018-11-16 2021-08-18 메모리얼 슬로안 케터링 캔서 센터 뮤신-16에 대한 항체 및 이의 사용 방법
SG11202105403XA (en) 2018-11-27 2021-06-29 Staidson Beijing Biopharmaceuticals Co Ltd Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
CN111375057B (zh) * 2018-12-28 2024-06-21 上海复宏汉霖生物技术股份有限公司 一种包含抗Her2单克隆抗体的药物配制剂
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
KR20250171463A (ko) 2019-02-11 2025-12-08 아센디스 파마 그로우쓰 디스오더스 에이/에스 Cnp 접합체의 건조 약학 제제
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
AU2020311511B2 (en) 2019-07-09 2024-08-29 Beijing Solobio Genetechnology Co., Ltd. Antibodies specifically recognizing Pseudomonas PcrV and uses thereof
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP3808777A1 (en) 2019-10-16 2021-04-21 Glenmark Specialty S.A. Stable liquid antibody formulations
CA3165026A1 (en) 2020-01-17 2021-07-22 Jinan Li Method for treatment of nerve injury and related disease
KR20220137950A (ko) 2020-02-06 2022-10-12 탈렌젠 인터내셔널 리미티드 다발성 경화증의 예방 및 치료 방법 및 약물
WO2021170067A1 (zh) 2020-02-28 2021-09-02 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
CN115151573A (zh) 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
CN115666612A (zh) 2020-03-24 2023-01-31 泰伦基国际有限公司 一种治疗亨廷顿病的方法和药物
WO2021190562A1 (zh) 2020-03-24 2021-09-30 泰伦基国际有限公司 一种促进错误折叠蛋白及其聚集物降解的方法和药物
CA3176934A1 (en) 2020-03-24 2021-09-30 Talengen International Limited Method and drug for treating parkinson's disease
EP4122488A4 (en) 2020-03-24 2023-04-05 Talengen International Limited METHOD AND MEDICATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CN113993900B (zh) 2020-05-27 2023-08-04 舒泰神（北京）生物制药股份有限公司 特异性识别神经生长因子的抗体及其用途
JP2023529842A (ja) 2020-06-02 2023-07-12 ダイナミキュア バイオテクノロジー エルエルシー 抗ｃｄ９３構築物およびその使用
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
IL298731A (en) * 2020-06-12 2023-02-01 Ichnos Sciences S A Antibody Diluent Formulation
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
KR20230030621A (ko) 2020-06-29 2023-03-06 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
TWI896700B (zh) 2020-07-10 2025-09-11 大陸商上海濟煜醫藥科技有限公司 一種抗IgE的工程化抗體及其應用
EP4188550A1 (en) 2020-07-29 2023-06-07 Dynamicure Biotechnology LLC Anti-cd93 constructs and uses thereof
AU2021324842A1 (en) 2020-08-14 2023-03-02 F. Hoffmann-La Roche Ag Methods for treating multiple sclerosis with ocrelizumab
CN114246944A (zh) * 2020-09-24 2022-03-29 盛禾(中国)生物制药有限公司 一种双特异性抗体的药物组合物及其用途
CN118146382A (zh) 2020-09-28 2024-06-07 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
WO2022109087A1 (en) * 2020-11-20 2022-05-27 Genentech, Inc. Reusable cartridges for detecting analytes in solution
WO2022129301A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
CN112684177B (zh) * 2020-12-17 2024-05-28 北京维德维康生物技术有限公司 一种乳品多因子快速检测试剂盒及其检测方法
CN117715933A (zh) 2021-03-05 2024-03-15 当康生物技术有限责任公司 抗vista的构建体及其用途
CN117616041A (zh) 2021-03-25 2024-02-27 当康生物技术有限责任公司 抗-igfbp7构建体及其用途
US12227574B2 (en) 2021-06-17 2025-02-18 Amberstone Biosciences, Inc. Anti-CD3 constructs and uses thereof
WO2023283611A1 (en) 2021-07-08 2023-01-12 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
KR20240058075A (ko) 2021-07-14 2024-05-03 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Cd40을 특이적으로 식별하는 항체 및 이의 응용
WO2023019556A1 (zh) * 2021-08-20 2023-02-23 齐鲁制药有限公司 一种高浓度抗her2的抗体制剂及其用途
EP4445911A4 (en) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
US20250326828A1 (en) 2022-05-09 2025-10-23 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies Specifically Recognizing Gdf15 and Uses Thereof
TW202417503A (zh) 2022-07-19 2024-05-01 美商舒泰神（加州）生物科技有限公司 特異性識別ｂ和ｔ淋巴細胞衰減器（ｂｔｌａ）的抗體及其應用
CA3262492A1 (en) 2022-08-19 2024-02-22 Evive Biotechnology (Shanghai) Ltd Formulations containing G-CSF and their uses
JP2025531788A (ja) 2022-09-07 2025-09-25 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａコンストラクト及びその使用
EP4596580A4 (en) 2022-09-27 2026-01-21 Staidson Beijing Biopharmaceuticals Co Ltd ANTIBODIES TO SPECIFICALLY RECOGNIZE LIGHT LIGANDS AND THEIR USE
CN120693395A (zh) 2022-10-20 2025-09-23 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
CN115746082B (zh) * 2022-12-02 2024-12-10 大连工业大学 一种调控糖基化鳕鱼蛋白结构的方法及其在制备高内相乳液中的应用
CN121311247A (zh) 2023-06-09 2026-01-09 舒泰神（北京）生物制药股份有限公司 特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体
WO2024255794A1 (zh) 2023-06-16 2024-12-19 舒泰神（北京）生物制药股份有限公司 特异性识别因子XIIa的抗体及其应用
TW202517294A (zh) 2023-07-11 2025-05-01 美商建南德克公司 用於治療多發性硬化症之組成物及方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896028A (ja) * 1981-11-30 1983-06-07 Takeda Chem Ind Ltd ヒトＩｇＥの製造法
US4482483A (en) * 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0779694B2 (ja) * 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH0827283B2 (ja) * 1986-03-10 1996-03-21 財団法人化学及血清療法研究所 免疫凝集反応用組成物
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
JPS62289523A (ja) * 1986-06-09 1987-12-16 Green Cross Corp:The 静脈投与用免疫グロブリンの加熱処理方法
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5262296A (en) * 1988-03-30 1993-11-16 Toray Industries, Inc. Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
JPH01268645A (ja) * 1988-04-18 1989-10-26 Teijin Ltd シュワルツマン反応抑制剤
JPH03504605A (ja) * 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
CN1047342A (zh) * 1989-05-13 1990-11-28 杭州市中心血站 因子viii的生产及其病毒灭活方法
EP0478715B1 (en) * 1989-06-23 1996-04-03 The Liposome Company, Inc. Targeted liposomes and methods for liposome-protein coupling
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
JP3290660B2 (ja) * 1991-10-11 2002-06-10 アボツト・ラボラトリーズ 特異的結合検定用の使用単位試薬組成物
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5290764A (en) * 1992-01-14 1994-03-01 The Dupont Merck Pharmaceutical Company Stabilization of active plasminogen activator inhibitor-1
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
WO1994019020A1 (en) * 1993-02-23 1994-09-01 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
FR2708467B1 (fr) * 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
WO1995033488A1 (en) 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation

Also Published As

Publication number Publication date
AR074517A2 (es) 2011-01-26
DK2275119T3 (da) 2013-11-11
JP2016033156A (ja) 2016-03-10
NO323557B1 (no) 2007-06-11
AU6599296A (en) 1997-02-26
CN1539505A (zh) 2004-10-27
JP5043506B2 (ja) 2012-10-10
JP2017039778A (ja) 2017-02-23
IL122910A0 (en) 1998-08-16
JP2011256205A (ja) 2011-12-22
CN1191490A (zh) 1998-08-26
EP1516628B1 (en) 2013-08-21
JPH11510170A (ja) 1999-09-07
RU2497500C2 (ru) 2013-11-10
NZ313503A (en) 2000-01-28
JP2007217430A (ja) 2007-08-30
BR9609743A (pt) 1999-03-02
CN1151842C (zh) 2004-06-02
CA2226575C (en) 2011-10-18
CN100360184C (zh) 2008-01-09
EP2275119B1 (en) 2013-09-25
NO323557B3 (no) 2007-06-11
EP1516628A1 (en) 2005-03-23
PT1516628E (pt) 2013-09-24
RU2013141049A (ru) 2015-03-20
JP5043507B2 (ja) 2012-10-10
WO1997004801A1 (en) 1997-02-13
AR003969A1 (es) 1998-09-30
CN102416176A (zh) 2012-04-18
NO2007012I1 (no) 2007-11-29
CA2745743A1 (en) 1997-02-13
HK1117075A1 (en) 2009-01-09
MX9800684A (es) 1998-04-30
CA2226575A1 (en) 1997-02-13
ES2434840T3 (es) 2013-12-17
JP2007238628A (ja) 2007-09-20
EP0845997A1 (en) 1998-06-10
EP2275119A1 (en) 2011-01-19
SI1516628T1 (sl) 2013-10-30
JP2011256206A (ja) 2011-12-22
ES2435462T3 (es) 2013-12-19
HK1152876A1 (en) 2012-03-16
PT2275119E (pt) 2013-11-21
IL122910A (en) 2002-05-23
NO980335L (no) 1998-03-26
DK1516628T3 (da) 2013-09-08
NZ500539A (en) 2001-11-30
AU716785B2 (en) 2000-03-09
SI2275119T1 (sl) 2013-12-31

Similar Documents

Publication Publication Date Title
NO980335D0 (no) Stabilt isotont lyofilisert proteinpreparat
AR104198A2 (es) Formulaciones de proteínas y anticuerpos de alta concentración
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
AU2002324556A1 (en) Stable lyophilized pharmaceutical formulation of igg antibodies
ATE131042T1 (de) Pharmakologische zubereitung, enthaltend polyelektrolytkomplexe in mikropartikulärer form und mindestens einen wirkstoff.
MY111682A (en) Altered antibodies and their preparations.
Pincus et al. Antibodies to type III and type VIII pneumococcal polysaccharides: evidence for restricted structural heterogeneity in hyperimmunized rabbits
ES2090052T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y uso.
US5017558A (en) Synthetic vaccine peptide epitomes of hepatitis B surface antigen
FI884240A0 (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
DK270389D0 (da) Lyofiliseret igm-koncentrat
NO900758D0 (no) Fremgangsmaate for fremstilling av hybridprotein.
Hoffmann et al. Preparation of human and murine monoclonal antibodies: antigens combined with or conjugated to lipopeptides constitute potent immunogens for in vitro and in vivo immunizations
Dobson et al. Immunoglobulin E antibodies in guinea pigs: Characterization of monomeric and polymeric components
KR910016347A (ko) C형 간염 바이러스에 대한 초면역 글로블린 및 이의 제조방법
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
EP0101562A2 (en) Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
JPS63225320A (ja) 抗体を含有する安定水性組成物
Ohmori Effects of interleukin 4 on an antigen-specific IgE response in vitro in murine lymphocytes
DK1226176T3 (da) Produktion af brystsekret-antistoffer i landbrugsdyr
DE69322960D1 (de) Empfängnisverhütender impfstoff
RU95104722A (ru) Способ получения антител к коринебактериям дифтерии
Humphrey Rodney R. Porter, 1917–1985

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Spc suppl protection certif: SPC/NO 2007 012

Filing date: 20071105

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2007012

Effective date: 20161129